High hydrostatic pressure induces immunogenic cell death in human tumor cells

International Journal of Cancer

Volumn 135, Issue 5, 2014, Pages 1165-1177

  Fucikova, Jitka ^a,b   Moserova, Irena ^b   Truxova, Iva ^b   Hermanova, Ivana ^a   Vancurova, Irena ^b   Partlova, Simona ^b   Fialova, Anna ^a,b   Sojka, Ludek ^a,b   Cartron, Pierre Francois ^c   Houska, Milan ^d   Rob, Lukas ^a   Bartunkova, Jirina ^a,b   Spisek, Radek ^a,b  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b Sotio   (Czech Republic)

^c INSERM   (France)

^d FOOD RESEARCH INSTITUTE PRAGUE   (Czech Republic)

Author keywords

cancer immunotherapy; dendritic cells; heat shock proteins; high hydrostatic pressure; immunogenic cell death

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALRETICULIN; CASPASE 8; CD83 ANTIGEN; CD86 ANTIGEN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HIGH MOBILITY GROUP B1 PROTEIN; HLA DR ANTIGEN; IDARUBICIN; INITIATION FACTOR 2ALPHA; INTERLEUKIN 12P70; INTERLEUKIN 6; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL; CELL INTERACTION; CELL SURFACE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HYDROSTATIC PRESSURE; IMMUNOGENIC CELL DEATH; LEUKEMIA CELL; LYMPHOCYTE COUNT; OVARY CANCER; PHAGOCYTOSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; THERAPY EFFECT; TUMOR CELL; ULTRAVIOLET B RADIATION; UPREGULATION;

CANCER IMMUNOTHERAPY; DENDRITIC CELLS; HEAT SHOCK PROTEINS; HIGH HYDROSTATIC PRESSURE; IMMUNOGENIC CELL DEATH;

ADENOSINE TRIPHOSPHATE; ANTIGENS, CD; ANTIGENS, CD86; APOPTOSIS; CALRETICULIN; CASPASE 8; CELL LINE, TUMOR; DENDRITIC CELLS; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; EUKARYOTIC INITIATION FACTOR-2; HLA-DR ANTIGENS; HMGB1 PROTEIN; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYDROSTATIC PRESSURE; IMMUNOGLOBULINS; INTERLEUKIN-12; INTERLEUKIN-6; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; NEOPLASMS; PHAGOCYTOSIS; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84902543448     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28766     Document Type: Article

References (50)

1. Green DR, Ferguson T, Zitvogel L, et al. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009; 9: 353-63.
2. Krysko DV, Vandenabeele P,. From regulation of dying cell engulfment to development of anti-cancer therapy. Cell Death Differ 2008; 15: 29-38.
3. Zitvogel L, Tesniere A, Kroemer G,. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6: 715-27.
4. Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8: 59-73.
5. Fucikova J, Kralikova P, Fialova A, et al. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 2011; 71: 4821-33.
6. Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29: 482-91.
7. Spisek R, Charalambous A, Mazumder A, et al. Bortezomib enhances dendritic cell (DC) mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 2007; 109: 4839-45.
8. Galluzzi L, Kepp O, Kroemer G,. Enlightening the impact of immunogenic cell death in photodynamic cancer therapy. EMBO J 2012; 31: 1055-7.
9. Spisek R, Dhodapkar MV,. Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells. Cell Cycle 2007; 6: 1962-5.
10. Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31: 51-72.
11. Lehner T, Wang Y, Whittall T, et al. Functional domains of HSP70 stimulate generation of cytokines and chemokines, maturation of dendritic cells and adjuvanticity. Biochem Soc Trans 2004; 32: 629-32.
12. Masse D, Ebstein F, Bougras G, et al. Increased expression of inducible HSP70 in apoptotic cells is correlated with their efficacy for antitumor vaccine therapy. Int J Cancer 2004; 111: 575-83.
13. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54-61.
14. Krysko DV, Garg AD, Kaczmarek A, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12: 860-75.
15. Lanneau D, Brunet M, Frisan E, et al. Heat shock proteins: essential proteins for apoptosis regulation. J Cell Mol Med 2008; 12: 743-61.
16. Hickman-Miller HD, Hildebrand WH,. The immune response under stress: the role of HSP-derived peptides. Trends Immunol 2004; 25: 427-33.
17. Panaretakis T, Kepp O, Brockmeier U, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009; 28: 578-90.
18. Kepp O, Tesniere A, Schlemmer F, et al. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 2009; 14: 364-75.
19. Martins I, Kepp O, Galluzzi L, et al. Surface-exposed calreticulin in the interaction between dying cells and phagocytes. Ann NY Acad Sci 2010; 1209: 77-82.
20. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-9.
21. Park JS, Gamboni-Robertson F, He Q, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol 2006; 290: C917-C924.
22. Joffre O, Nolte MA, Sporri R, et al. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev 2009; 227: 234-47.
23. Aymeric L, Apetoh L, Ghiringhelli F, et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res 2010; 70: 855-8.
24. Martins I, Tesniere A, Kepp O, et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle 2009; 8: 3723-8.
25. Garg AD, Krysko DV, Verfaillie T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012; 31: 1062-79.
26. Rozkova D, Tiserova H, Fucikova J, et al. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer. Clin Immunol 2009; 131: 1-10.
27. Nouri-Shirazi M, Banchereau J, Fay J, et al. Dendritic cell based tumor vaccines. Immunol Lett 2000; 74: 5-10.
28. Boura E, Liebl D, Spisek R, et al. Polyomavirus EGFP-pseudocapsids: analysis of model particles for introduction of proteins and peptides into mammalian cells. FEBS Lett 2005; 579: 6549-58.
29. Mattarollo SR, Loi S, Duret H, et al. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 2011; 71: 4809-20.
30. Garg AD, Krysko DV, Vandenabeele P, et al. Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol Immunother 2012; 61: 215-21.
31. Moserova I, Kralova J,. Role of ER stress response in photodynamic therapy: ROS generated in different subcellular compartments trigger diverse cell death pathways. PLoS One 2012; 7: e32972.
32. Garg AD, Krysko DV, Vandenabeele P, et al. The emergence of phox-ER stress induced immunogenic apoptosis. Oncoimmunology 2012; 1: 786-88.
33. Garg AD, Krysko DV, Vandenabeele P, et al. DAMPs and PDT-mediated photo-oxidative stress: exploring the unknown. Photochem Photobiol Sci 2011; 10: 670-80.
34. Garg AD, Nowis D, Golab J, et al. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta 2010; 1805: 53-71.
35. Krysko DV, Vandenabeele P,. Clearance of dead cells: mechanisms, immune responses and implication in the development of diseases. Apoptosis 2010; 15: 995-7.
36. Tesniere A, Panaretakis T, Kepp O, et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2008; 15: 3-12.
37. Yang D, Chen Q, Yang H, et al. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 2007; 81: 59-66.
38. Castano AP, Mroz P, Hamblin MR,. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 2006; 6: 535-45.
39. Frey B, Janko C, Ebel N, et al. Cells under pressure-treatment of eukaryotic cells with high hydrostatic pressure, from physiologic aspects to pressure induced cell death. Curr Med Chem 2008; 15: 2329-36.
40. Weiss EM, Meister S, Janko C, et al. High hydrostatic pressure treatment generates inactivated mammalian tumor cells with immunogeneic features. J Immunotoxicol 2010; 7: 194-204.
41. Aertsen A, Meersman F, Hendrickx ME, et al. Biotechnology under high pressure: applications and implications. Trends Biotechnol 2009; 27: 434-41.
42. Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202: 1691-701.
43. Ghiringhelli F, Apetoh L, Housseau F, et al. Links between innate and cognate tumor immunity. Curr Opin Immunol 2007; 19: 224-31.
44. Klein O, Ebert LM, Zanker D, et al. Flt3 ligand expands CD4(+) FoxP3(+) regulatory T cells in human subjects. Eur J Immunol 2013; 43: 533-9.
45. Agostinis P, Buytaert E, Breyssens H, et al. Regulatory pathways in photodynamic therapy induced apoptosis. Photochem Photobiol Sci 2004; 3: 721-9.
46. Gollnick SO, Vaughan L, Henderson BW,. Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res 2002; 62: 1604-8.
47. Fucikova J, Rozkova D, Ulcova H, et al. Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials. J Transl Med 2011; 9: 223.
48. Tobiasova Z, Pospisilova D, Miller AM, et al. In vitro assessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients. Clin Immunol 2007; 122: 18-27.
49. Vacchelli E, Vitale I, Eggermont A, et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013; 2: e25771.
50. Fialova A, Partlova S, Sojka L, et al. Dynamics of T-cell infiltration during the course of ovarian cancer: the gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells. Int J Cancer 2013; 132: 1070-9.